GlassScriptPhysician profile
William J Leland
NPI 1780664060
$3,390.08
in general payments reported to CMS, 2019-2025
28 companies · $256 in 2025
The $256 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $396 · 2021: $705 · 2022: $317 · 2023: $597 · 2024: $580 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,432.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,024.56 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $447.31 | 2019-2024 | Entyvio |
| Cook Medical LLC | $220.07 | 2019-2025 | Hemospray, Echotip Insight, Echotip |
| Pfizer INC. | $210.96 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $190.92 | 2019-2024 | Xifaxan |
| Gilead Sciences, INC. | $190.79 | 2019-2024 | |
| Intercept Pharmaceuticals, INC. | $175.08 | 2019-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $161.82 | 2019-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $94.85 | 2020-2024 | Linzess |
| Boston Scientific Corporation | $82.62 | 2019 | |
| Braintree Laboratories, INC. | $78.70 | 2019-2021 | |
| Janssen Biotech, INC. | $77.74 | 2019-2024 | Simponi, Simponi Aria, Stelara |
| Ardelyx, INC. | $61.27 | 2024-2025 | Ibsrela |
| Pentax of America, INC. | $58.60 | 2025 | Pentax Medical, Inspira, C2 Cryoballoon |
| Nestle Healthcare Nutrition INC. | $42.03 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $39.63 | 2020-2021 | |
| Celgene Corporation | $32.43 | 2021-2023 | Zeposia |
| Fresenius Kabi USA, LLC | $25.16 | 2023 | Idacio |
| Genzyme Corporation | $24.07 | 2024 | |
| Allergan, INC. | $23.41 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $20.49 | 2019 | |
| Ucb, INC. | $18.76 | 2019 | |
| Intra-Sana Laboratories | $18.75 | 2021 | |
| Aimmune Therapeutics, INC. | $16.36 | 2024 | |
| Ferring Pharmaceuticals INC. | $14.54 | 2023 | Rebyota |
| Dynavax Technologies Corporation | $14.27 | 2022 | |
| Phathom Pharmaceuticals, INC. | $12.84 | 2024 | Voquezna |
| Amgen INC. | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Leland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.